Review Finds No Clear Link Between Acetaminophen in Pregnancy and Autism, ADHD
A recent review has concluded that there is no clear association between acetaminophen use during pregnancy and the development of autism or ADHD in children. This topic gained attention following claims made by President Donald Trump in September, where he suggested that the medication could significantly increase autism risk.
Key Findings on Acetaminophen Use in Pregnancy
The review, published in the BMJ, analyzed multiple systematic reviews conducted by researchers from institutions in the U.K., Spain, and Australia. These reviews collectively examined 40 studies related to maternal acetaminophen use and child neurodevelopment.
Previous Claims and Studies
- The claims connecting acetaminophen and neurodevelopmental disorders have been discussed since an August 2025 meta-analysis.
- This earlier analysis suggested potential links between prenatal acetaminophen exposure and disorders like autism and ADHD.
- Despite these claims, the new review found insufficient evidence to draw a causal link.
Assessment of Reviewed Studies
The review scrutinized nine systematic reviews regarding their methodology and findings. It identified critical flaws in several, including a lack of comprehensive literature searches and inadequate consideration of excluded studies.
Dr. Shakila Thangaratinam, a co-author of the new review, emphasized the importance of accurate interpretations of existing research. Many previous studies did not account for factors such as genetics and maternal health, which can influence neurodevelopmental outcomes.
Expert Opinions
Major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG), have publicly criticized Trump’s statements. They described his assertions as irresponsible and unsupported by scientific evidence.
Dr. Thangaratinam indicated that misleading information could cause pregnant individuals to avoid acetaminophen when necessary, potentially jeopardizing both maternal and fetal health. Some may resort to using other medications, like ibuprofen, which are not recommended for use during pregnancy.
Underlying Issues in Drug Safety During Pregnancy
One of the review’s significant points is the general lack of safe medication options for pregnant women. Dr. Thangaratinam highlighted the ongoing challenges in drug development for this demographic, stating that pregnant women are often excluded from clinical trials.
This exclusion limits the understanding of medication safety during pregnancy. The review calls for renewed focus on drug discovery and research to ensure that safe and effective treatments are available for pregnant individuals.
